Compare Cassava Sciences Inc (FLNA) vs Kohl's Corporation (KSS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Kohl's Corporation — how do they compare? Cassava Sciences Inc trades at $1.1 (market cap $53.14M), while Kohl's Corporation trades at $17.52 (market cap $1.94B). The key difference: Kohl's Corporation is far larger — about 36.5× Cassava Sciences Inc's market cap, and Kohl's Corporation pays a 2.92% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | KSS | |
|---|---|---|
Market Cap | $53.14M | $1.94B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.64 | $24.71 |
52-Week Low | $1.09 | $9.39 |
Enterprise Value | -$33.43M | $8.04B |
Dividend Yield | — | 2.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Kohl's (KSS) trades at $17.62, up 7.31% in the past 24 hours, with a bullish technical signal from moving averages. The stock shows deep value with a P/E of 7.18 and P/B of 0.48, while recent earnings beats and a 10% jump in juniors sales (Zacks, 2026-06-30) signal early turnaround progress. Cash flow improved to $276M net in 2026 from -$49M in 2025, though revenue has declined from $19.4B in 2022 to $16.2B in 2025.
The outlook hinges on successful execution of Kohl's value-focused strategy and proprietary brand growth to reverse sales declines. Risks include intense retail competition and macroeconomic pressure on consumer spending. Analysts are mixed with a $16.75 consensus target below the current price, suggesting cautious optimism amid restructuring efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Kohl's Corporation
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →
